Headquartered in New York, Lokavant offers a Clinical Trial Intelligence Platform that aggregates real-time and historical trial data to power predictive analytics and operational applications. The platform leverages a proprietary data asset covering more than 2,000 studies, 14,000+ investigators, and 12,000 healthcare institutions alongside integrated real-world data. Lokavant says its analytics drive a 70x improvement in enrollment-forecast accuracy, over $1 million in cost savings from patient retention, and six months' time savings from detecting site noncompliance. The company recently launched a Study Planning solution and began a collaboration with a top-10 pharmaceutical customer. With plans to open an APAC headquarters in Tokyo, Lokavant is expanding into Japan and the broader Asia‑Pacific market with product localization and regional staffing support. Lokavant is a clinical intelligence platform that enables real-time integration and harmonization of clinical trial data for study planning and operations. The company aggregates and integrates real-time data from disparate trial data sources and powers advanced analytics using its compendium of proprietary trial data. Its suite of applications supports data-driven study planning, benchmarking, operational health assessments, risk detection, medical monitoring, and vendor oversight. Clinical researchers access the platform via use-case-specific applications to proactively plan and manage studies and surface insights. Lokavant plans to use the $21M in funding to scale its commercial teams and accelerate feature development for its platform. The company is led by CEO Rohit Nambisan and is based in Princeton, NJ.

Total raised

$29M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2023